Post-operative AF after cardiac surgery
New-onset AF after cardiac surgery in adults. Most often on days 2-4.
All Pathways
Cardiothoracic SurgeryManagement
Post-Operative Atrial Fibrillation after Cardiac Surgery (ACC/AHA 2023, ESC 2024)
Post-Operative Atrial Fibrillation after Cardiac Surgery (ACC/AHA 2023, ESC 2024): Post-operative AF after cardiac surgery → Assess: 12-lead ECG, haemod...
Pathway Overview
12 steps
Algorithm Steps
12 total
01Start 02Action Assess: 12-lead ECG, haemodynamics, triggers
Confirm AF on a 12-lead ECG. Look for pre-excitation and AV block.
- BP, perfusion, urine output, lactate; signs of heart failure or ischaemia
- Ventricular rate, symptoms and AF onset time (over 24 h matters for cardioversion; ACC/AHA uses 48 h)
- Bloods: K+ and Mg2+ (mmol/L), Hb; TSH for new AF
- Triggers: hypoxia, pain, hypovolaemia, bleeding, pericardial effusion, infection, inotropes
- Check epicardial pacing wires and whether the usual beta-blocker was stopped
03Warning Before rate or rhythm drugs: check for pre-excitation, low output, heart block
Adult doses in this pathway. Amiodarone: not if iodine allergy; in hyperthyroidism only if no other option.
- Pre-excited AF (WPW): no beta-blocker, diltiazem, verapamil, digoxin, adenosine or IV amiodarone; DC cardioversion
- Hypotension, low cardiac output or on inotropes: no IV beta-blocker bolus or calcium channel blocker; IV amiodarone or DC cardioversion
- Bradycardia or AV block (common after valve surgery): pace via epicardial wires before rate-slowing drugs
04Warning If unstable: synchronised DC cardioversion now
Unstable: hypotension, shock, ischaemia or acute heart failure due to AF. Look for tamponade, bleeding or graft ischaemia. Do not delay for anticoagulation.
- Sedation by a skilled clinician; synchronised biphasic shock, first shock 200 J or more
- Fails or AF recurs: amiodarone (adult) 300 mg IV in 5% glucose over 10-20 min, repeat shock, then 900 mg IV over 24 h
- Bradycardia after the shock: pace via epicardial wires or transcutaneous pacing
05Action Stable, or AF recurs after cardioversion: rate control, beta-blocker first
Target resting HR under 100 bpm (ACC/AHA); under 110 bpm is acceptable (ESC). No verapamil or diltiazem if LVEF 40% or less. On any beta-blocker (oral or IV): no IV verapamil outside ICU (risk of asystole and hypotension). Severe asthma or bronchospasm: no beta-blocker.
- Metoprolol (adult) 2.5-5 mg IV over 2 min; repeat to a maximum of 15 mg total (1 mg/mL ampoule)
- Then metoprolol tartrate 25-100 mg orally twice daily; restart the usual beta-blocker
- LVEF 40% or less or low output: amiodarone (adult) 300 mg IV in 250 mL 5% glucose over 30-60 min, then 900-1200 mg in 500-1000 mL 5% glucose over 24 h (central line preferred). Already had the IV load in the unstable step: do not repeat it; continue the infusion
- Or digoxin (adult) 0.5 mg IV; total 0.75-1.5 mg over 24 h in divided doses; lower dose in renal impairment; with amiodarone, lower the digoxin dose and check levels and ECG
- Beta-blocker fails or not tolerated, LVEF over 40%: oral diltiazem or verapamil. IV verapamil 2.5-10 mg over 5 min only if on no beta-blocker (oral or IV), or in ICU with monitoring and pacing wires
06Action All patients: correct triggers
Treat the causes of POAF with rate or rhythm control.
- Replace K+ and Mg2+ (mmol/L) to local targets
- Treat hypoxia, pain, hypovolaemia, anaemia and infection
- Echo if pericardial effusion or tamponade is possible
- Wean inotropes if able; do not stop beta-blockers abruptly
07Decision Rhythm control needed?
Yes if AF is poorly tolerated, symptoms persist or rate control fails. When stable, rate and rhythm control give similar outcomes.
- If Yes
08Action Rhythm control: amiodarone and/or DC cardioversion
AF over 24 h (ESC 2024; ACC/AHA uses 48 h) and not anticoagulated: TOE to exclude LA appendage thrombus before elective cardioversion. Anticoagulate at cardioversion and for at least 4 weeks after, when bleeding risk allows.
- Amiodarone (adult) 300 mg IV in 250 mL 5% glucose over 30-60 min, then 900-1200 mg IV in 500-1000 mL 5% glucose over 24 h (central line preferred). Already loaded (unstable step or rate control): do not repeat the IV load
- Oral, in place of or after the IV infusion: amiodarone 200 mg three times daily for up to 4 weeks (IV doses count toward the load), then 200 mg daily or less
- Amiodarone can cause hypotension, bradycardia, AV block and QT prolongation
- Do not use flecainide after cardiac surgery with structural or coronary heart disease
- DC cardioversion (synchronised, 200 J or more) if drugs fail
09Decision Anticoagulation indicated and safe?
Indicated: POAF after cardiac surgery, for about 60 days (ACC/AHA). After any cardioversion: at least 4 weeks, even in sinus rhythm (optional only if AF under 24 h and no stroke risk factors). Long term if CHA2DS2-VA 2 or more. Safe: surgical bleeding risk has settled (ask the surgical team).
- If Yes
10Action Anticoagulate when surgical bleeding risk allows
Mechanical valve or moderate-severe mitral stenosis: warfarin only, no DOAC. Others: DOAC preferred over warfarin (including valve repair), dosed for renal function. On aspirin or a P2Y12 inhibitor (after CABG or PCI): review with cardiology; do not combine with the anticoagulant without a clear indication.
- Agree the start time with the surgical team (drains, pericardial bleeding)
- Bioprosthetic valve in the last 3 months: valve guidelines favour warfarin; DOAC may be considered (agree with the surgeon)
- Full DOAC dose unless drug-specific criteria for a lower dose are met (CrCl, age, weight)
- Amiodarone raises INR: check INR more often and adjust warfarin
- Duration: at least 60 days after surgery, then reassess rhythm and stroke risk
11Action All patients: discharge and follow-up
Many patients return to sinus rhythm within 6-8 weeks.
- Rhythm check (ECG) at 30-60 days
- Still in AF: consider cardioversion after adequate anticoagulation
- Long-term anticoagulation by CHA2DS2-VA and bleeding risk; POAF raises later AF and stroke risk
- Not anticoagulated because of bleeding: reassess before discharge
- Stop amiodarone when no longer needed
- Cardiology follow-up if AF persists or recurs
12Outcome Sinus rhythm, or ongoing AF care
Persistent or recurrent AF: manage as AF (AF-CARE).
If No- Path rejoins step 11Shared downstream outcome
If No- Path rejoins step 09Shared downstream outcome
Guideline Source
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, section 10.9 (AF after cardiac surgery); with 2024 ESC AF guideline, section 9.6
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Adults after cardiac surgery only; AF after non-cardiac surgery is managed as trigger-induced AF
- Does not cover prevention of POAF (continue beta-blockers, amiodarone prophylaxis, posterior pericardiotomy)
- Evidence that anticoagulation prevents stroke in POAF is limited; timing depends on surgical bleeding risk
- Electrolyte targets follow local protocol
Contraindicated Populations
children (paediatric post-operative arrhythmias need a paediatric protocol)AF after non-cardiac surgery (use a general AF pathway)
Applicable Regions
AUUSEU
AU: IV diltiazem and ibutilide are not on the ARTG. IV metoprolol 5 mg/5 mL, verapamil 5 mg/2 mL, amiodarone 150 mg/3 mL, digoxin 500 microgram/2 mL are on the ARTG. K+ and Mg2+ in mmol/L.
EU: ESC 2024: lenient rate target under 110 bpm; stroke risk by CHA2DS2-VA.
US: ACC/AHA 2023: rate target under 100 bpm after cardiac surgery; stroke risk by CHA2DS2-VASc.
Version 2Next review: 2027-09-30
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Post-Operative Atrial Fibrillation after Cardiac Surgery (ACC/AHA 2023, ESC 2024)?
The Post-Operative Atrial Fibrillation after Cardiac Surgery (ACC/AHA 2023, ESC 2024) is a management clinical algorithm for Cardiothoracic Surgery. It provides a structured decision tree to guide clinical decision-making, based on 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, section 10.9 (AF after cardiac surgery); with 2024 ESC AF guideline, section 9.6.
What guideline is the Post-Operative Atrial Fibrillation after Cardiac Surgery (ACC/AHA 2023, ESC 2024) based on?
This algorithm is based on 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, section 10.9 (AF after cardiac surgery); with 2024 ESC AF guideline, section 9.6 (DOI: 10.1161/CIR.0000000000001193).
What are the limitations of the Post-Operative Atrial Fibrillation after Cardiac Surgery (ACC/AHA 2023, ESC 2024)?
Known limitations include: Adults after cardiac surgery only; AF after non-cardiac surgery is managed as trigger-induced AF; Does not cover prevention of POAF (continue beta-blockers, amiodarone prophylaxis, posterior pericardiotomy); Evidence that anticoagulation prevents stroke in POAF is limited; timing depends on surgical bleeding risk; Electrolyte targets follow local protocol. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Post-Operative Atrial Fibrillation after Cardiac Surgery (ACC/AHA 2023, ESC 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free